Eric Kaneps, Vice President of Sales & Marketing at Renaissance Lakewood, recently shared insights into the company’s expansion and focus on nasal spray technology.
Speaking to PharmaSource at CPHI Milan, he explained that the US-based CDMO has completed a significant expansion of their New Jersey headquarters, including a new 67,000 square foot warehouse and a dedicated R&D building. This expansion enhances their capabilities in formulation development, analytical work, and spray testing.
“We focus specifically on nasal sprays, and we also do sterile injectable products,” Eric explains. Renaissance Lakewood offers a range of nasal spray options, including unit dose, bi-dose, microdose, multidose preserved, and multidose preservative-free aseptic nasal sprays. The company is exploring innovative applications, such as replacing auto-injectors with nasal delivery systems for certain molecules, potentially improving patient convenience and compliance.
Looking ahead to 2025, Eric identifies patient compliance as a key market trend. “It’s really about making products that patients can use and understand,” he states. He notes that nasal delivery is gaining acceptance in the US market, which has traditionally favoured oral solid dose medications.
Renaissance Lakewood’s expansion and focus on nasal spray technology position the company to meet growing demand and drive innovation in drug delivery systems. As Eric concludes, “When someone comes to us with an idea, we can explore the best way to deliver their product nasally, optimising formulations and selecting the most appropriate medical device for effective delivery.”
Stay ahead of trends and best practices
